My apologies jakay.
Calm yourself, I prefer not to hijack someone's thread, but since you opened the door I'll respond and I will get this conversation split into a new thread. You're not the only trans woman here, as I am too, most are at Breastnexum. I've been on NBE for 3 years and developed a D-cup, then went on HRT for 4 years and am a DDD-cup now. I attached a recent photo where we were discussing how well estrogen cream helps with nipple projection.
![[Image: hk9nh9sFFph71POzQRnsx_wKYYgkh_N0TXCoul-H...6u8RTpZtQF]](https://lh5.googleusercontent.com/hk9nh9sFFph71POzQRnsx_wKYYgkh_N0TXCoul-HppE7yKotVOr596Y5ljuavw66bbORRaFh9Q4hJXLU3c3ICxKNCiPqzED_rsWz0YdWBDwn1SuRTmqpzpxvIsIBxj6u8RTpZtQF)
![[Image: CVsNQe44QaQs62zMNad_bmAPwiF2ZE_Rdv3nb0td...ipd_hWFouT]](https://lh4.googleusercontent.com/CVsNQe44QaQs62zMNad_bmAPwiF2ZE_Rdv3nb0td1tD9mwVwdOfWQL3oxUViH_syNFadZQl3vJdbcKA9WSkABP4CMa5tZ2f-v3WnKo35TqBNuXmEPGcmdQXMoFvQCaipd_hWFouT)
I see you've had breast augmentation, were you taking spiro. I'm glad your doctor prescribed progesterone. Spironolactone isn't in a trans woman's best interest. Go to Reddit and look up Dr. Will Powers and read his cutting edge treatment plan, it doesn't include spiro. I used spironolactone and it wasn't for me.
Spironolactone
Spironolactone is not very selective against other steroid receptors such as AR and PR. In particular, its anti-progesterone and anti-androgen properties lead to unwanted side effects such as gynecomastia, breast pain, menstrual irregularities, and impotence, thus limiting its use [2,11].
https://www.sciencedirect.com/topics/che...onolactone
The Case Against Spironolactone
https://moderntranshormones.com/2018/01/...nolactone/
Spironolactone, an antiandrogen commonly used by trans women in the United States, has been associated with a greater likelihood of seeking breast augmentation.
https://genderanalysis.net/resources/stu...velopment/
Hormonal Treatment of Transgender Women with Oral Estradiol
Spironolactone did not aid testosterone suppression and seemed to impair achievement of goal serum 17-β estradiol levels.
https://pubmed.ncbi.nlm.nih.gov/29756046/
Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens
L J Seal et al. J Clin Endocrinol Metab. 2012 Dec.
Context: Breast development in transwomen is an important issue, affecting general psychological functioning. Current hormonal therapies are imperfect, with 60% of patients requesting mammoplasty.
Interventions: Interventions included the following: 1) comparing the effects on trans women's requests for mammoplasty of estrogen valerate, ethinylestradiol, and conjugated equine estrogen (CEE) hormone treatments; and 2) comparing the effects of GnRH analogs and androgen antagonists.
Objective: The objective of the study was to identify which hormone regimen is associated with the greatest subsequent request for augmentation mammoplasty.
Design: The study was a controlled, retrospective case audit.
Setting: The study was conducted at a single-center National Health Service tertiary care unit.
Patients: Patients were eligible for breast augmentation after 2 yr of estrogen treatment, were Tanner IV or higher breast development, and reported psychological distress due to small breasts. One hundred sixty-five subjects and 165 age-matched controls were identified.
Outcome measure: The outcome measure was a mammoplasty request.
Results: There were significantly more self-medicating individuals than controls in the mammoplasty group (11.5 vs. 6%, P < 0.05). The type of estrogen use did not affect the outcome. Compared with other antiandrogens, spironolactone use was significantly higher in those requesting mammoplasty (4.8 vs. 1.8%, P = 0.002). Thromboembolism occurred in 1.2% of individuals, more frequently in those treated with CEE than in those treated with either estrogen valerate or ethinylestradiol (4.4 vs. 0.6 vs. 0.7%, P = 0.026). Depression was noted in approximately 30% of individuals.
Conclusions: Self-medication with estrogen is significantly more likely to result in a later request for mammoplasty than is treatment prescribed by licensed practitioners. Previous spironolactone use is more common in those requesting mammoplasty. CEE treatment is associated with a higher incidence of thromboembolism than treatment with other estrogen types.
Calm yourself, I prefer not to hijack someone's thread, but since you opened the door I'll respond and I will get this conversation split into a new thread. You're not the only trans woman here, as I am too, most are at Breastnexum. I've been on NBE for 3 years and developed a D-cup, then went on HRT for 4 years and am a DDD-cup now. I attached a recent photo where we were discussing how well estrogen cream helps with nipple projection.
I see you've had breast augmentation, were you taking spiro. I'm glad your doctor prescribed progesterone. Spironolactone isn't in a trans woman's best interest. Go to Reddit and look up Dr. Will Powers and read his cutting edge treatment plan, it doesn't include spiro. I used spironolactone and it wasn't for me.
Spironolactone
Spironolactone is not very selective against other steroid receptors such as AR and PR. In particular, its anti-progesterone and anti-androgen properties lead to unwanted side effects such as gynecomastia, breast pain, menstrual irregularities, and impotence, thus limiting its use [2,11].
https://www.sciencedirect.com/topics/che...onolactone
The Case Against Spironolactone
https://moderntranshormones.com/2018/01/...nolactone/
Spironolactone, an antiandrogen commonly used by trans women in the United States, has been associated with a greater likelihood of seeking breast augmentation.
https://genderanalysis.net/resources/stu...velopment/
Hormonal Treatment of Transgender Women with Oral Estradiol
Spironolactone did not aid testosterone suppression and seemed to impair achievement of goal serum 17-β estradiol levels.
https://pubmed.ncbi.nlm.nih.gov/29756046/
Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens
L J Seal et al. J Clin Endocrinol Metab. 2012 Dec.
Context: Breast development in transwomen is an important issue, affecting general psychological functioning. Current hormonal therapies are imperfect, with 60% of patients requesting mammoplasty.
Interventions: Interventions included the following: 1) comparing the effects on trans women's requests for mammoplasty of estrogen valerate, ethinylestradiol, and conjugated equine estrogen (CEE) hormone treatments; and 2) comparing the effects of GnRH analogs and androgen antagonists.
Objective: The objective of the study was to identify which hormone regimen is associated with the greatest subsequent request for augmentation mammoplasty.
Design: The study was a controlled, retrospective case audit.
Setting: The study was conducted at a single-center National Health Service tertiary care unit.
Patients: Patients were eligible for breast augmentation after 2 yr of estrogen treatment, were Tanner IV or higher breast development, and reported psychological distress due to small breasts. One hundred sixty-five subjects and 165 age-matched controls were identified.
Outcome measure: The outcome measure was a mammoplasty request.
Results: There were significantly more self-medicating individuals than controls in the mammoplasty group (11.5 vs. 6%, P < 0.05). The type of estrogen use did not affect the outcome. Compared with other antiandrogens, spironolactone use was significantly higher in those requesting mammoplasty (4.8 vs. 1.8%, P = 0.002). Thromboembolism occurred in 1.2% of individuals, more frequently in those treated with CEE than in those treated with either estrogen valerate or ethinylestradiol (4.4 vs. 0.6 vs. 0.7%, P = 0.026). Depression was noted in approximately 30% of individuals.
Conclusions: Self-medication with estrogen is significantly more likely to result in a later request for mammoplasty than is treatment prescribed by licensed practitioners. Previous spironolactone use is more common in those requesting mammoplasty. CEE treatment is associated with a higher incidence of thromboembolism than treatment with other estrogen types.